|
業務類別
|
Biotechnology |
|
業務概覽
|
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study. |
| 公司地址
| 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127 |
| 電話號碼
| +1 305 509-6897 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.verupharma.com |
| 員工數量
| 20 |
| Dr. Mitchell S. Steiner, F.A.C.S.,PhD |
Chairman of the Board, President and Chief Executive Officer |
美元 836.21K |
28/01/2026 |
| Mr. K. Gary Barnette, PhD |
Chief Scientific Officer |
美元 615.62K |
28/01/2026 |
| Ms. Michele Greco |
Principal Accounting Officer, Chief Financial Officer and Chief Administrative Officer |
-- |
28/01/2026 |
| Dr. Harry Fisch, M.D. |
Vice Chairman of the Board and Chief Corporate Officer |
美元 505.63K |
28/01/2026 |
|
|
| Mr. Michael L. Rankowitz |
Independent Director |
28/01/2026 |
| Dr. Mitchell S. Steiner, F.A.C.S.,PhD |
Chairman of the Board, President and Chief Executive Officer |
28/01/2026 |
| Dr. Lucy Lu, M.D. |
Independent Director |
28/01/2026 |
| Mr. Loren Mark Katzovitz |
Independent Director |
28/01/2026 |
| Dr. Harry Fisch, M.D. |
Vice Chairman of the Board and Chief Corporate Officer |
28/01/2026 |
| Ms. Grace S. Hyun, M.D. |
Independent Director |
28/01/2026 |
|
|
|
|
